Safety of C1-inhibitor for clinical use.
Hack
C Erik
CE
de Zwaan
Chris
C
Hermens
Wim T
WT
D000818:Animals; D000990:Antithrombin III / Q000187:drug effects; D003167:Complement Activation / Q000187:drug effects; D003174:Complement C1 Inactivator Proteins / Q000009:adverse effects* / Q000627:therapeutic use; D050718:Complement C1 Inhibitor Protein; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D017202:Myocardial Ischemia / Q000188:drug therapy; D010447:Peptide Hydrolases / Q000187:drug effects; D010865:Pilot Projects; D012306:Risk; D013552:Swine; D016896:Treatment Outcome
D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases